Small molecule inhibitors (Tivantinib and INC280), on the other hand, inhibit signaling by interfering with the tyrosine kinase activity of the MET receptor.479–481 Targeting the HGF/MET pathway with biological antagonists, monoclonal antibodies, and small molecule inhibitors offers promising therapeutic avenues for inhibiting tumor growth and metastasis. Here, MET is linked to neoplasm.